Want to see ETON full AI Analyst Report?
ETON Stock Chart & Stats
$25.04
-$0.03(-0.25%)
At close: 4:00 PM EST
$25.04
-$0.03(-0.25%)
Day’s Range― - ―
52-Week Range$13.76 - $38.62
Previous CloseN/A
Volume127.06K
Average Volume (3M)394.98K
Market Cap
$1.00B
Enterprise Value$889.96M
Total Cash (Recent Filing)$19.66M
Total Debt (Recent Filing)$12.25M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 06, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding27,392,359
10 Day Avg. Volume385,002
30 Day Avg. Volume394,981
Financial Highlights & Ratios
PEG Ratio-7.46
Price to Book (P/B)17.40
Price to Sales (P/S)5.69
P/FCF Ratio44.65
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue10.24
Enterprise Value/Gross Profit18.69
Enterprise Value/Ebitda163.18
Forecast
1Y Price Target
$48.50Price Target Upside93.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.8
Revenue Forecast (FY)$113.39M
Bulls Say, Bears Say
Bulls Say
Revenue Scale & Margin ProfileA multi-year revenue ramp to nearly $87M TTM with mid‑50% gross margins indicates durable commercial traction in niche specialty markets. Scale supports operating leverage, funds reinvestment, and makes margin targets (70%+ adjusted) achievable as higher-margin launches mature.
Improving Balance Sheet & FinancingMeaningful debt reduction and asset growth materially improve financial flexibility. Lower leverage reduces refinancing and covenant risk, enabling targeted M&A, sustained R&D spend, and patient-support investments without immediate dilutive financing if cash generation continues.
Orphan/Pediatrics Portfolio & PipelineA diversified orphan/pediatric franchise with recent launches plus multiple late‑stage catalysts creates several durable revenue levers. Orphan focus supports premium pricing, specialty distribution, and sticky patient programs that can sustain higher margins and long‑term market share.
Bears Say
Ongoing GAAP LossesDespite improved EBITDA and scale, GAAP net losses persist, keeping ROE negative. Continued inability to deliver consistent GAAP profitability can constrain reinvestment capacity, investor confidence, and limit available retained capital for longer‑term projects absent sustained cash generation.
HEMANGEOL Reimbursement & Mix RiskA large share of expected HEMANGEOL volume potentially yielding little or no net revenue creates durable uncertainty in realized pricing and revenue growth. Payer coverage, patient assistance mix, and specialty pharmacy deployment can materially alter long‑term revenue per patient and peak sales assumptions.
Cash Flow Volatility & Near‑Term LiquidityPositive FCF exists but is volatile and recently stepped down, and a sizable acquisition used material cash. This leaves a tighter near‑term runway and heightens reliance on ongoing commercial execution and amended credit terms to fund R&D, launches, and working capital without resorting to dilutive financing.
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals’s price range in the past 12 months?
Eton Pharmaceuticals lowest stock price was $13.76 and its highest was $38.62 in the past 12 months.
What is Eton Pharmaceuticals’s market cap?
Eton Pharmaceuticals’s market cap is $1.00B.
When is Eton Pharmaceuticals’s upcoming earnings report date?
Eton Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 22 days.
How were Eton Pharmaceuticals’s earnings last quarter?
Eton Pharmaceuticals released its earnings results on May 14, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.113 by $0.027.
Is Eton Pharmaceuticals overvalued?
According to Wall Street analysts Eton Pharmaceuticals’s price is currently Undervalued.
Does Eton Pharmaceuticals pay dividends?
Eton Pharmaceuticals does not currently pay dividends.
What is Eton Pharmaceuticals’s EPS estimate?
Eton Pharmaceuticals’s EPS estimate is 0.15.
How many shares outstanding does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 27,392,359 shares outstanding.
What happened to Eton Pharmaceuticals’s price movement after its last earnings report?
Eton Pharmaceuticals reported an EPS of $0.14 in its last earnings report, beating expectations of $0.113. Following the earnings report the stock price went up 1.001%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals?
Currently, no hedge funds are holding shares in ETON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eton Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.50 (93.69% Upside)
$48.50 (93.69% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 75.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.28%
12-Months-Change
Fundamentals
Return on Equity
-5.68%
Trailing 12-Months
Asset Growth
16.28%
Trailing 12-Months
Company Description
Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Stock 12 Month Forecast
Average Price Target
$48.50
▲(93.69% Upside)
Technical Analysis
Ownership Overview
14.98% Insiders
6.90% Mutual Funds
1.54% Other Institutional Investors
67.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---